{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:08:35Z","timestamp":1788390515118,"version":"build-2803163510"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Chimeric antigen receptor T-cell (CAR-T) therapy is a paradigm-changing therapy in treating non-Hodgkin lymphoma (NHL). Although NHL is a leading cause of cancer-attributable deaths for persons living with HIV (PWH) in high-income countries, PWH are frequently excluded from CAR-T clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore access to CAR-T trials for the general population and PWH.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study queried ClinicalTrials.gov for all interventional CAR-T clinical trials for the treatment of NHL. Zip codes for each trial site were extracted, and travel time to the nearest location was calculated. Trials included had at least 1 trial site in the contiguous US, and were actively recruiting trials for adult patients (aged \u226518 years) as of May 20, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n All trials were reviewed for relevance and eligibility of PWH.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcomes were median population-weighted travel time to the nearest trial and 1-hour and 3-hour access for the general population, HIV-inclusive trials, and HIV-exclusive trials. Proportions were compared using a \u03c7\n 2<\/jats:sup>\n test, and continuous median travel times were compared using unpaired\n t<\/jats:italic>\n tests.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In total, 254 trials were eligible for review, and 80 met criteria for inclusion with 11 (13.8%) trials including PWH, 58 (72.5%) excluding PWH, and 11 (13.8%) not mentioning HIV. The median (IQR) population-weighted travel time was 0.73 (0.36-1.64) hours for the general population, 1.15 (0.49-2.38) hours for trials including PWH, and 0.84 (0.40-1.91) hours for trials excluding PWH. Compared with trials that excluded PWH, trials that included PWH had significantly lower 1-hour (46.07% [95% CI, 46.06%-46.07%] vs 55.27% [95% CI, 55.27%-55.28%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and 3-hour (82.22% [95% CI, 82.22%-82.23%] vs 87.76% [95% CI, 87.75%-87.76%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) access. Travel time in the South was significantly longer for trials that included PWH compared with trials that excluded PWH (median [IQR], 1.70 [0.69-2.99] hours vs 0.92 [0.46-2.00] hours;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cross-sectional study of travel time to CAR-T trials found that PWH had to travel significantly longer than the general population to reach the nearest trial. Despite efforts to reduce clinical trial exclusion based solely on HIV status, access for PWH remains disproportionately lower compared with the general population, and particularly poor in the South, where there is the highest prevalence of HIV. Further efforts to increase access to trials for underserved and underrepresented populations, particularly for PWH, are needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.14265","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:30:23Z","timestamp":1779463823000},"page":"e2614265","source":"Crossref","is-referenced-by-count":1,"title":["Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma for Persons With HIV"],"prefix":"10.1001","volume":"9","author":[{"given":"Luke","family":"Maillie","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sisk","sequence":"additional","affiliation":[{"name":"Lucy Family Institute for Data & Society, University of Notre Dame, Notre Dame, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Coghill","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Van Bibber","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen E.","family":"Guerra","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Aboulafia","sequence":"additional","affiliation":[{"name":"Virginia Mason Medical Center, Seattle, Washington"},{"name":"Community Advisory Board, University of Washington Positive Research, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Velazquez","sequence":"additional","affiliation":[{"name":"Community Advisory Board, University of Washington Positive Research, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"1","key":"zoi260417r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v9i1.647","article-title":"Chimeric antigen receptor (CAR)-T cell therapy for non-hodgkin\u2019s lymphoma.","volume":"9","author":"Giraudo","year":"2024","journal-title":"Pathog Immun"},{"issue":"26","key":"zoi260417r2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260417r3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"zoi260417r4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"zoi260417r5","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium.","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260417r6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260417r7","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"10343","key":"zoi260417r8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"zoi260417r9","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"zoi260417r10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamainternmed.2014.6300","article-title":"Geographic accessibility to clinical trials for advanced cancer in the United States.","volume":"175","author":"Galsky","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"9","key":"zoi260417r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.33188","article-title":"Travel time and distance and participation in precision oncology trials at the National Cancer Center Hospital.","volume":"6","author":"Uehara","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi260417r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma.","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi260417r13","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2024-212286","article-title":"Disparity in access to myeloma CAR-T: a geospatial analysis of distance to CAR-T centers and its impact on mortality.","volume":"144","author":"Daunov","year":"2024","journal-title":"Blood"},{"issue":"7","key":"zoi260417r14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers.","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"zoi260417r15","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","article-title":"Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies.","volume":"11","author":"Trickey","year":"2024","journal-title":"Lancet HIV"},{"issue":"9","key":"zoi260417r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1742","article-title":"HIV infection, cancer treatment regimens, and cancer outcomes among elderly adults in the United States.","volume":"5","author":"Coghill","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi260417r17","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1093\/cid\/ciaa1016","article-title":"Deaths attributable to cancer in the US human immunodeficiency virus population during 2001-2015.","volume":"72","author":"Horner","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi260417r18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1158\/1055-9965.EPI-16-0964","article-title":"Excess mortality among HIV-infected individuals with cancer in the United States.","volume":"26","author":"Coghill","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"zoi260417r19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/COH.0000000000000320","article-title":"Cancer care disparities in people with HIV in the United States.","volume":"12","author":"Suneja","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"issue":"15","key":"zoi260417r20","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.23.02366","article-title":"Cancer treatment disparities in people With HIV in the United States, 2001-2019.","volume":"42","author":"McGee-Avila","year":"2024","journal-title":"J Clin Oncol"},{"issue":"33","key":"zoi260417r21","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi260417r22","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"2","key":"zoi260417r23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/07357907.2025.2462568","article-title":"Exclusion of people living with HIV in aggressive B-Cell non-hodgkin lymphoma studies: a cross-sectional analysis of clinical trials from 2014 to 2024.","volume":"43","author":"Olivieri","year":"2025","journal-title":"Cancer Invest"},{"issue":"4","key":"zoi260417r25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cncr.23229","article-title":"Geographic access to cancer care in the U.S.","volume":"112","author":"Onega","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"zoi260417r26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10916-017-0850-0","article-title":"Disparities in geographic accessibility of National Cancer Institute Cancer Centers in the United States.","volume":"41","author":"Xu","year":"2017","journal-title":"J Med Syst"},{"issue":"17","key":"zoi260417r28","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/cncr.30727","article-title":"Population-based geographic access to parent and satellite National Cancer Institute Cancer Center Facilities.","volume":"123","author":"Onega","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"zoi260417r30","doi-asserted-by":"publisher","first-page":"455.e1","DOI":"10.1016\/j.jtct.2024.02.003","article-title":"Serial evaluation of preimmunization antibody titers in lymphoma patients receiving chimeric antigen receptor T cell therapy.","volume":"30","author":"Bansal","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"zoi260417r31","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1182\/blood-2022-165370","article-title":"Observational cohort study of people living with HIV (PWH) treated with CD19-directed CAR T cell therapy for B-Cell lymphoid malignancies: interim results of AIDS Malignancy Consortium (AMC) study AMC-113.","volume":"140","author":"Barta","year":"2022","journal-title":"Blood"},{"issue":"4","key":"zoi260417r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8739","article-title":"Barriers to clinical trial implementation among community care centers.","volume":"7","author":"Ebrahimi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi260417r33","doi-asserted-by":"publisher","first-page":"12788","DOI":"10.1182\/blood-2022-157292","article-title":"Trial-in-progress: AMC 112: axicabtagene ciloleucel in relapsed or refractory HIV-associated aggressive B-Cell Non-Hodgkin Lymphoma (NCT05077527).","volume":"140","author":"Epstein-Peterson","year":"2022","journal-title":"Blood"},{"issue":"2","key":"zoi260417r34","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jtct.2023.12.049","article-title":"Acalabrutinib in combination with Anti-CD19 chimeric antigen receptor t-cell therapy in relapsed\/refractory B-Cell Lymphoma: a phase i\/ii study of safety, efficacy and immune correlative analysis.","volume":"30","author":"Poh","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"zoi260417r35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment.","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"zoi260417r24","unstructured":"Open Source Routing Machine. Modern C++ routing engine for shortest paths in road networks. Accessed April 10, 2026. https:\/\/project-osrm.org"},{"key":"zoi260417r27","unstructured":"AIDSVu.org. Datasets. Accessed May 29, 2025. https:\/\/aidsvu.org\/"},{"key":"zoi260417r29","unstructured":"U.S. Department of Health and Human Services: Food and Drug Administration. Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B virus, or hepatitis C virus infections. 2020. Accessed April 10, 2026. https:\/\/www.fda.gov\/media\/121319\/download"},{"key":"zoi260417r36","unstructured":"United States Census Bureau. P1 total population table. Accessed April 14, 2026. https:\/\/data.census.gov\/table"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849284\/maillie_2026_oi_260417_1778857509.00558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:30:25Z","timestamp":1779463825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.14265","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}